Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Feugier

Showing results (51-60 of 164) with videos related to

Pageof 17
Sort By:
Blood|July 3, 2004
Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiationPierre Feugier, Eric Labouyrie, Malika Djeridane, et al.
Blood|September 19, 2008
Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 studyGilles Salles, Nicolas Mounier, Sophie de Guibert, et al.
Blood|December 20, 2008
Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcomeBruno Chetaille, François Bertucci, Pascal Finetti, et al.
Blood|May 30, 2015
High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphomaMarie-Hélène Delfau-Larue, Wolfram Klapper, Françoise Berger, et al.
Haematologica|May 7, 2013
Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphomaEmmanuel Bachy, Roch Houot, Franck Morschhauser, et al.
Annals of Hematology|November 5, 2024
Six-year follow-up of phase II study exploring chemo-free treatment association with idelalisib and obinutuzumab in symptomatic relapsed/ refractory patients with Waldenström's macroglobulinemiaCécile Tomowiak, Stéphanie Poulain, Morgane Nudel, et al.
Blood|May 4, 2010
Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA studyFabrice Jardin, Jean-Philippe Jais, Thierry-Jo Molina, et al.
American Journal of Hematology|March 16, 2017
Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) groupAnne-Sophie Michallet, Arnaud Campidelli, Helene Lequeu, et al.
Annals of Hematology|March 5, 2024
Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE studyCaroline Dartigeas, Anne Quinquenel, Loïc Ysebaert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2023
Predictive Value of Minimal Residual Disease for Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results From the European Mantle Cell Lymphoma Elderly TrialEva Hoster, Marie-Hélène Delfau-Larue, Elizabeth Macintyre, et al.
Pageof 17

Showing results (51-60 of 164) with videos related to

Sort By:
Pageof 17
Blood|July 3, 2004
Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiationPierre Feugier, Eric Labouyrie, Malika Djeridane, et al.
Blood|September 19, 2008
Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 studyGilles Salles, Nicolas Mounier, Sophie de Guibert, et al.
Blood|December 20, 2008
Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcomeBruno Chetaille, François Bertucci, Pascal Finetti, et al.
Blood|May 30, 2015
High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphomaMarie-Hélène Delfau-Larue, Wolfram Klapper, Françoise Berger, et al.
Haematologica|May 7, 2013
Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphomaEmmanuel Bachy, Roch Houot, Franck Morschhauser, et al.
Annals of Hematology|November 5, 2024
Six-year follow-up of phase II study exploring chemo-free treatment association with idelalisib and obinutuzumab in symptomatic relapsed/ refractory patients with Waldenström's macroglobulinemiaCécile Tomowiak, Stéphanie Poulain, Morgane Nudel, et al.
Blood|May 4, 2010
Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA studyFabrice Jardin, Jean-Philippe Jais, Thierry-Jo Molina, et al.
American Journal of Hematology|March 16, 2017
Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) groupAnne-Sophie Michallet, Arnaud Campidelli, Helene Lequeu, et al.
Annals of Hematology|March 5, 2024
Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE studyCaroline Dartigeas, Anne Quinquenel, Loïc Ysebaert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2023
Predictive Value of Minimal Residual Disease for Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results From the European Mantle Cell Lymphoma Elderly TrialEva Hoster, Marie-Hélène Delfau-Larue, Elizabeth Macintyre, et al.
Pageof 17